Precision Biosciences (DTIL) Non-Current Debt (2021 - 2026)

Precision Biosciences (DTIL) has 6 years of Non-Current Debt data on file, last reported at $22.4 million in Q1 2026.

• On a quarterly basis, Non-Current Debt changed 0.37% year-over-year to $22.4 million in Q1 2026; TTM through Mar 2026 was $22.4 million, a 0.37% change from a year earlier, with the FY2025 full-year figure at $22.4 million, changed 0.37% from the prior year.
• Non-Current Debt for Q1 2026 stood at $22.4 million, roughly flat from $22.4 million in the prior quarter.
• Over the last five years, Non-Current Debt for DTIL reached as high as $22.4 million in Q1 2026 and fell as low as $2.5 million in Q1 2022.
• Historically, Non-Current Debt has averaged $20.6 million across 5 years, with a median of $22.3 million in 2024.
• Across the five-year window, Non-Current Debt surged 797.26% in 2023 and advanced 0.37% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $22.2 million in 2022, then advanced by 0.21% to $22.3 million in 2023, then increased by 0.23% to $22.3 million in 2024, then gained by 0.37% to $22.4 million in 2025, then gained by 0.07% to $22.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $22.4 million in Q1 2026, $22.4 million in Q4 2025, and $22.4 million in Q3 2025.